Explore more publications!

Press Releases

Generic Pharmaceuticals Contract Manufacturing Market to Reach USD 143.22 Billion by 2035, Driven by Demand for Affordable Therapies
Pharmaceutical Bottles Market Report for Packaging Companies
Dietary Supplements Market Size Expected to Reach USD 430.39 Bn by 2034 Driven by Preventive Healthcare, Personalized Nutrition, and Rising Health Awareness
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
The 3D-Flow Architecture Breakthrough: A Universal, Scalable Digital Processor for Real-Time Pattern Recognition in High-Rate Data Streams — A Platform to Save Millions of Lives and Billions of Euros
Trends in Pharmaceutical Cold Chain Logistics Packaging Market
NovelWise Pharma Announces First Patient Dosed in Phase I/II Trial of NBM-BMX for Metastatic Uveal Melanoma
China, Japan, S. Korea to meet this weekend despite Taiwan tensions

China, Japan, S. Korea to meet this weekend despite Taiwan tensions

Medical Devices Market Size Worth USD 1,209.42 Bn by 2035 Fueled by Advances in Diagnostic Technologies
Taiwan’s 2025 Mobileheroes Competition Winners Announced: Seizing 5G and AI Market Opportunities in Taiwan and Asia
Avalue MAB Series Delivers Scalable Medical-Grade Edge Intelligence for Precision Care
mRNA Quality Monitoring Market to Reach USD 2.5 Billion by 2034, Driven by Expanding Healthcare Applications
Trends in Sterile Medical Packaging Market 2025-2035
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN
Real-World Data (RWD) Market Size Worth USD 6.37 Bn by 2034 Driven by AI Adoption, Precision Medicine, and Drug Development Demand
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
rYojbaba Subsidiary Sakai Seikotsuin Serves as an Official Trainer at the 2025 Taipei Wake Open
Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions